Psychedelic/entactogen-assisted therapy for treatment of anxiety, depression and existential distress in adult palliative care
Sivan Schipper, Kabir Nigam, Vanessa Piechotta, Michael Ljuslin, Yvan Beaussant, Guido Schwarzer, Christopher Boehlke
Cochrane Database of Systematic Reviews November 21, 2022 DOI: 10.1002/14651858.cd015383 via OpenAlex
Summary
AI-generated from the abstractThis Cochrane protocol outlines a planned review to evaluate whether psychedelic- or entactogen-assisted therapy is beneficial and safe for adults in palliative care who suffer from anxiety, depression, or existential distress. The review will compare such therapy against placebo or active treatments like antidepressants. The protocol describes the methods for searching and analyzing studies, but no results are reported yet.
Study at a glance
| Characteristics | Systematic review protocol Peer reviewed |
|---|---|
| Topics | Anxiety |
| Keywords | Distress Depression economics Palliative care Psychotherapist |
| Citations | 4 |
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of psychedelic/entactogen‐assisted therapy compared to placebo or active comparators (e.g. antidepressants) for treatment of anxiety, depression, and existential distress in adult palliative care.